Study guide

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications

Key Takeaways Explain This Topic AI

Diagnostic criteria for Type 2 Diabetes Mellitus require a Fasting Plasma Glucose (FPG) ≥126 mg/dL, a 2-hour 75g Oral Glucose Tolerance Test (OGTT) ≥200 mg/dL, an HbA1c ≥6.5%, or a random plasma glucose ≥200 mg/dL in the presence of classic hyperglycemic symptoms; asymptomatic results mandate confirmatory repeat testing.

Pharmacotherapy algorithms from the ADA prioritize organ-protection independent of baseline HbA1c: patients with established ASCVD, high cardiovascular risk, Heart Failure (HFrEF/HFpEF), or Chronic Kidney Disease (CKD) should receive an SGLT2 inhibitor and/or a GLP-1 receptor agonist with proven cardiovascular/renal benefit.

Metformin remains a cornerstone first-line insulin-sensitizing biguanide; it is contraindicated when eGFR <30 mL/min/1.73 m², requires a 50% dose reduction and close monitoring when eGFR is 30–44 mL/min/1.73 m², and necessitates periodic Vitamin B12 level surveillance to prevent peripheral neuropathy and megaloblastic anemia.

Diabetic Kidney Disease (DKD) is screened annually via spot urine albumin-to-creatinine ratio (UACR) and estimated GFR; persistent albuminuria (UACR ≥30 mg/g) mandates ACE inhibitor or ARB titration (never combined), SGLT2 inhibitor therapy down to eGFR 20 mL/min, and consideration of non-steroidal mineralocorticoid receptor antagonists (Finerenone).

Diabetic autonomic and peripheral neuropathies require annual 10g Semmes-Weinstein monofilament plus vibration testing; painful peripheral neuropathy is managed with first-line duloxetine, pregabalin, or gabapentin, whereas non-dihydropyridine calcium channel blockers and tight glycemic control prevent Charcot joint progression.

Last updated: October 2026

Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications

Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive, multi-system metabolic disorder characterized by peripheral insulin resistance, progressive pancreatic β \beta β -cell secretory failure, accelerated hepatic gluconeogenesis, and systemic low-grade inflammation. The disease accounts for over 90% of all diagnosed diabetes cases across adult and geriatric populations in the United States. Uncontrolled hyperglycemia drives widespread vascular endothelial injury, making T2DM the leading cause of new-onset end-stage renal disease (ESRD), non-traumatic lower-extremity amputations, and adult-onset blindness, while conferring a two- to four-fold increase in atherosclerotic cardiovascular morbidity and mortality.

For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , board certification demands mastery of current American Diabetes Association (ADA) Standards of Care in Diabetes , including precise diagnostic criteria, individualized glycemic goals, organ-protective pharmacotherapy selection algorithms, insulin initiation and titration mechanics, and proactive microvascular surveillance protocols.

1. Pathophysiology: The Ominous Octet & Metabolic Derangements

Historically conceptualized as a dual defect of muscle insulin resistance and β \beta β -cell exhaustion, modern diabetology recognizes the multi-organ pathophysiological schema known as DeFronzo's "Ominous Octet" (further expanded to the Egregious Eleven): +---------------------------------------------------------------------------------------------------+

  • | THE OMINOUS OCTET OF TYPE 2 DIABETES |
  • | |
  • | 1. PANCREATIC BETA-CELLS ---> Progressive loss of mass and secretory dysfunction (insulopenia)|
  • | 2. SKELETAL MUSCLE ---> Impaired GLUT-4 translocation; diminished glucose uptake |
  • | 3. LIVER ---> Unchecked hepatic gluconeogenesis and glycogenolysis |
  • | 4. ADIPOCYTES ---> Accelerated lipolysis; elevated circulating free fatty acids |
  • | 5. GASTROINTESTINAL TRACT ---> Diminished incretin effect (GLP-1 & GIP deficiency/resistance) |
  • | 6. PANCREATIC ALPHA-CELLS ---> Hyperglucagonemia driving postprandial hepatic glucose output |
  • | 7. KIDNEYS ---> Upregulated SGLT2 cotransporters; increased glucose reabsorption|
  • | 8. BRAIN / HYPOTHALAMUS ---> Neurotransmitter dysregulation, altered appetite and satiety |
  • +---------------------------------------------------------------------------------------------------+
  • Metabolic Synergies & Glucolipotoxicity

Insulin Resistance (Receptor and Post-Receptor Defects): Defective tyrosine kinase autophosphorylation of the insulin receptor and impaired intracellular signaling cascades (IRS-1, PI3K, Akt) inhibit the mobilization of glucose transporter type 4 ( GLUT-4 ) vesicles to the cell membranes of skeletal muscle and adipose tissue. This results in severe impairment of postprandial glucose disposal.

Hepatic Overproduction: In the fasting state, hepatic insulin resistance uncouples the normal inhibitory feedback on gluconeogenesis and glycogenolysis, mediated by unchecked phosphoenolpyruvate carboxykinase (PEPCK) activity, producing elevated fasting plasma glucose levels.

Lipotoxicity & β \beta β -Cell Apoptosis: Excess visceral adiposity causes chronic release of non-esterified free fatty acids (FFAs) and inflammatory adipokines (TNF- α \alpha α , IL-6, resistin). Ectopic lipid accumulation in pancreatic islets triggers endoplasmic reticulum stress, mitochondrial dysfunction, and accelerated β \beta β -cell apoptosis. By the time clinical fasting hyperglycemia manifests, approximately 50% of functional β \beta β -cell mass has already been irrevocably lost.

Incretin Dysfunction: The "incretin effect"—the physiological phenomenon whereby oral glucose stimulates substantially greater insulin secretion than an equivalent intravenous glucose load—is blunted or absent in T2DM due to impaired intestinal secretion and accelerated enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by dipeptidyl peptidase-4 (DPP-4).

2. ADA Diagnostic Criteria, Screening Recommendations & Hemoglobin A1c Nuances +---------------------------------------------------------------------------------------------------+

  • | ADA DIAGNOSTIC THRESHOLDS FOR GLYCEMIC STATUS |
  • | |
  • | DIAGNOSTIC TEST NORMAL PRE-DIABETES DIABETES MELLITUS |
  • | --------------------------------------------------------------------------------------------- |
  • | Fasting Plasma Glucose (FPG) < 100 mg/dL 100 - 125 mg/dL >= 126 mg/dL |
  • | 2-Hour 75g OGTT < 140 mg/dL 140 - 199 mg/dL >= 200 mg/dL |
  • | Hemoglobin A1c (HbA1c) < 5.7% 5.7% - 6.4% >= 6.5% |
  • | Random Plasma Glucose -- -- >= 200 mg/dL WITH |
  • | classic symptoms* |
  • | |
  • | *Classic Symptoms: Polyuria, polydipsia, polyphagia, unexplained weight loss, hyperglycemic crisis|
  • +---------------------------------------------------------------------------------------------------+

Critical Diagnostic Protocols:

Asymptomatic Patient Confirmation: In the absence of unequivocal symptomatic hyperglycemia (e.g., polyuria, polydipsia, weight loss) or acute hyperglycemic crisis, a diagnosis of diabetes requires two abnormal test results from either the same sample or two separate test samples (e.g., FPG ≥126 mg/dL and HbA1c ≥6.5% from the same blood draw, or repeat testing on a subsequent clinical encounter).

Discordant Results: If two different tests (e.g., FPG and HbA1c) are discordant, the test that is above the diagnostic threshold must be repeated, and the diagnosis is confirmed if the repeat value remains abnormal.

Population Screening Guidelines (USPSTF & ADA):

Universal Screening: Screen all asymptomatic non-pregnant adults beginning at age 35 (USPSTF Grade B; ADA recommends universal screening at age 35 for all individuals). Repeat testing at a minimum of 3-year intervals if results are normal.

Risk-Based Screening (Any Age): Screen adults of any age who are overweight or obese ( BMI ≥ 25 kg/m 2 \text{BMI} \ge 25\text{ kg/m}^2 BMI ≥ 25 kg/m 2 , or ≥ 23 kg/m 2 \ge 23\text{ kg/m}^2 ≥ 23 kg/m 2 in Asian Americans) who exhibit one or more additional risk factors:

First-degree relative with diabetes (parent or sibling).

High-risk race/ethnicity (African American, Hispanic/Latino, American Indian, Asian American, Pacific Islander).

History of Cardiovascular Disease (ASCVD).

Hypertension ( ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg or on antihypertensive therapy).

Dyslipidemia ( HDL-C < 35 mg/dL \text{HDL-C} < 35\text{ mg/dL} HDL-C < 35 mg/dL and/or fasting triglycerides > 250 mg/dL > 250\text{ mg/dL} > 250 mg/dL ).

History of Polycystic Ovary Syndrome (PCOS) or gestational diabetes mellitus (GDM).

Physical inactivity / sedentary lifestyle.

Conditions associated with severe insulin resistance (e.g., severe obesity, acanthosis nigricans).

Pre-diabetes on prior testing (screen annually).

Individuals with HIV (screen before starting antiretroviral therapy and at 3–6 month intervals).

Clinical Traps & Confounding Factors in HbA1c Measurement

Hemoglobin A1c quantifies the non-enzymatic glycation of the N-terminal valine of the hemoglobin β \beta β -chain over the erythrocyte lifespan (~120 days). Any condition altering erythrocyte turnover will introduce significant diagnostic artifacts:

Clinical Condition Impact on Measured HbA1c Underlying Pathophysiological Mechanism Alternative Testing Strategy

Hemolytic Anemia Falsely Decreased Shortened erythrocyte lifespan reduces cumulative glucose exposure time. Fructosamine (2-3 week glycation), continuous glucose monitoring (CGM), or serial FPG.

Acute Blood Loss / Transfusion Falsely Decreased Dilution of glycated RBCs with non-glycated reticulocytes/donor RBCs. Fructosamine or serial point-of-care capillary glucose profiles.

Chronic Hemodialysis / ESRD Falsely Decreased Uremic microenvironment, shortened RBC survival, erythropoietin therapy stimulating young RBCs. Continuous Glucose Monitoring (CGM) or Glycated Albumin / Fructosamine.

Severe Iron Deficiency Anemia Falsely Elevated Prolonged RBC circulation time and altered hemoglobin glycation dynamics. Treat iron deficiency, re-test after RBC repletion; use FPG/OGTT.

Hemoglobinopathies (HbS, HbC) Variable (Falsely High or Low) Altered electrophoretic mobility or assay interference depending on methodology. Use an NGSP-certified assay devoid of variant interference, or fructosamine.

Early / Late Pregnancy Falsely Decreased Accelerated erythrocyte turnover and lower fasting blood glucose levels. Fasting and postprandial capillary plasma glucose logs; 75g or 100g OGTT.

3. Individualized Glycemic Targets Across the Adult-Gerontology Lifespan

The ADA emphasizes individualization of glycemic goals based on patient age, life expectancy, comorbid conditions, micro/macrovascular disease burden, and hypoglycemia risk profile. +---------------------------------------------------------------------------------------------------+

  • | GLYCEMIC TARGET STRATIFICATION (ADA STANDARDS) |
  • | |
  • | CLINICAL PROFILE HbA1c TARGET FASTING GLUCOSE BEDTIME GLUCOSE |
  • | --------------------------------------------------------------------------------------------- |
  • | Healthy Non-Pregnant Adults < 7.0% 80 - 130 mg/dL 100 - 180 mg/dL |
  • | Younger / Short Duration / No CVD < 6.5% 80 - 120 mg/dL 100 - 140 mg/dL |
  • | Older Adults: Intact / Few Comorbid < 7.0 - 7.5% 80 - 130 mg/dL 100 - 180 mg/dL |
  • | Older Adults: Complex / Intermediate < 8.0% 90 - 150 mg/dL 100 - 180 mg/dL |
  • | Older Adults: Very Complex / Frail < 8.5% (or avoid 100 - 180 mg/dL 110 - 200 mg/dL |
  • | / End-Stage / Nursing Home hypoglycemia) |
  • +---------------------------------------------------------------------------------------------------+

Clinical Nuances of Glycemic Goals in Older Adults:

Avoiding Overtreatment and Iatrogenic Hypoglycemia: In older adults ( ≥ 65 years \ge 65\text{ years} ≥ 65 years ), severe hypoglycemia is associated with acute myocardial infarction, fatal ventricular arrhythmias, sudden cognitive collapse, and catastrophic fall-related hip fractures. When complex, frail older adults or patients with dementia are managed on sulfonylureas or insulin with HbA1c values < 6.5 % <6.5\% < 6.5% , the AGPCNP must actively de-intensify (deprescribe) therapy by tapering sulfonylureas or relaxing basal insulin doses.

Continuous Glucose Monitoring (CGM) Metrics: In patients utilizing CGM, target Time in Range (TIR, 70–180 mg/dL) > 70% , with Time Below Range (TBR, <70 mg/dL) < 4% , and Time < 54 mg/dL < 1% . For older or high-risk frail individuals, the target is adjusted to TIR > 50% and TBR (<70 mg/dL) < 1% .

4. Comprehensive Pharmacotherapy: Cardiorenal Risk-First Treatment Algorithm

The contemporary ADA algorithm decouples pharmacotherapy selection from initial HbA1c levels, prioritizing compelling organ-protective indications (Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease) at the moment of diagnosis. +---------------------------------------------------------------------------------------------------+

  • | ADA CARDIORENAL RISK-FIRST PHARMACOTHERAPY SELECTION |
  • | |
  • | [ESTABLISHED T2DM DIAGNOSIS + LIFESTYLE MODIFICATION] |
  • | | |
  • | +-------------------------------------+-------------------------------------+ |
  • | | | |
  • | v v |
  • | [HIGH CARDIORENAL RISK PRESENT] [NO HIGH CARDIORENAL] |
  • | (Established ASCVD, HF, or CKD) [RISK PRESENT] |
  • | | | |
  • | +----+--------------------------+-----------------------+ v |
  • | | | | [METFORMIN OR GLP-1 RA /]|
  • | v v v [SGLT2i BASED ON EFFICACY]|
  • | [ESTABLISHED ASCVD /] [HEART FAILURE] [CHRONIC KIDNEY] - Prioritize Weight Loss |
  • | [HIGH ASCVD RISK] (HFrEF or HFpEF) [DISEASE (CKD)] (Tirzepatide, Sema) |
  • | * GLP-1 RA with proven * SGLT2 inhibitor * SGLT2 inhibitor - Prioritize Cost / |
  • | CVD benefit (Sema, (Empa, Dapa, or (Empa, Dapa, or Access (Sulfonylurea, |
  • | Dula, Liraglutide) Bexagliflozin) Cana) with eGFR TZD, Generic DPP-4i) |
  • | OR proven benefit 20-60 or UACR >=30 - Prioritize Minimal |
  • | * SGLT2 inhibitor with + + Hypoglycemia Risk |
  • | proven CVD benefit * Add GLP-1 RA if * If SGLT2i not (DPP-4i, TZD, SGLT2i, |
  • | (Empa, Cana, Dapa) HbA1c above goal tolerated/at goal: GLP-1 RA) |
  • | * Combine both if Add GLP-1 RA |
  • | needed for goal or Finerenone |
  • +---------------------------------------------------------------------------------------------------+
  • Comprehensive Antihyperglycemic Drug Comparison Matrix

Drug Class & Prototype Agents Mechanism of Action Glycemic Efficacy ( Δ HbA1c \Delta\text{HbA1c} Δ HbA1c ) Cardiorenal & Weight Effects Adverse Effects & Clinical Cautions Renal Dosing Cutoffs & Contraindications

Biguanides ; • Metformin (Glucophage); 500–2,000 mg/day Activates AMP-activated protein kinase (AMPK); inhibits hepatic gluconeogenesis; enhances peripheral insulin sensitivity. High ; (1.0–1.5%) • Neutral / mild weight loss; • Neutral ASCVD/HF effect • GI distress (diarrhea, nausea, cramping - 20–30%); • Vitamin B12 deficiency (screen every 2–3 yrs) ; • Lactic acidosis (rare: 3–10 per 100,000) • Contraindicated if eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min ; • If eGFR 30–44: Max dose 1,000 mg/day; do not initiate; • Hold 48 hr post-IV iodinated contrast if eGFR <60

SGLT2 Inhibitors ; • Empagliflozin (10–25 mg); • Dapagliflozin (5–10 mg); • Canagliflozin (100–300 mg) Inhibits sodium-glucose cotransporter-2 in renal proximal convoluted tubule; blocks glucose & sodium reabsorption → \rightarrow → glucosuria. Intermediate ; (0.5–0.9%) • Superior HFrEF & HFpEF reduction ; • Slows CKD progression ; • ASCVD MACE reduction; • Weight loss (2–4 kg); • SBP reduction (3–5 mmHg) • Mycotic genital candidiasis (10–15%); • Volume depletion / orthostatic hypotension; • Euglycemic DKA (euDKA) ; • Fournier's gangrene (necrotizing fasciitis); • Bone fracture / amputation risk (canagliflozin) • Glycemic efficacy drops if eGFR <45, but cardiorenal protection preserved down to eGFR ≥ 20 mL/min \text{eGFR} \ge 20\text{ mL/min} eGFR ≥ 20 mL/min ; • Hold 3–4 days prior to scheduled major surgery to prevent euDKA

GLP-1 Receptor Agonists ; • Semaglutide (0.25–2.0 mg SubQ / 3–14 mg PO); • Dulaglutide (0.75–4.5 mg SubQ); • Liraglutide (0.6–1.8 mg SubQ) Activates GLP-1 receptors: glucose-dependent insulin secretion, glucagon suppression, slows gastric emptying, promotes central satiety. High to Very High ; (1.2–2.0%) • Superior ASCVD MACE reduction ; • Reduces albuminuria progression; • Profound Weight Loss (4–8+ kg) • GI: Nausea, vomiting, diarrhea, constipation; • Acute pancreatitis (rare); • Gallbladder disease / cholelithiasis; • Worsening diabetic retinopathy with rapid glucose drop • Black Box: Personal/family history of Medullary Thyroid Carcinoma (MTC) or MEN 2 ; • Severe gastroparesis; • No renal dose adjustment required (down to eGFR 15 for SubQ semaglutide)

Dual GIP / GLP-1 RA ; • Tirzepatide (Mounjaro); 2.5–15 mg SubQ weekly Synergistic twin incretin agonist (GIP + GLP-1 receptors); enhances insulin sensitivity, glucagon suppression, and centrally driven satiety. Very High ; (2.0–2.5%) • Unprecedented Weight Loss (10–22%) ; • Robust SBP, lipid, and ALT reductions; • SURPASS/SURMOUNT trial benefits • Dose-dependent GI distress (nausea, diarrhea); • Decreased oral contraceptive absorption (counsel barrier contraception x 4 wks post-initiation/escalation) • Black Box: Medullary Thyroid Carcinoma (MTC) / MEN 2 ; • History of severe pancreatitis; • Safe down to eGFR 15 mL/min

DPP-4 Inhibitors ; • Sitagliptin (100 mg); • Linagliptin (5 mg); • Saxagliptin (5 mg); • Alogliptin (25 mg) Inhibits dipeptidyl peptidase-4 enzyme; prolongs endogenous active GLP-1 and GIP half-life → \rightarrow → glucose-dependent insulin release. Intermediate ; (0.5–0.8%) • Weight neutral; • Neutral ASCVD effect; • Saxagliptin / Alogliptin: increased HF hospitalization risk • Nasopharyngitis, upper respiratory tract infections; • Severe, disabling joint pain / arthralgias; • Bullous pemphigoid; • Acute pancreatitis • Linagliptin: NO renal dose adjustment required (fecal excretion) ; • Sitagliptin: 50 mg if eGFR 30–44; 25 mg if eGFR <30; • Never combine DPP-4i + GLP-1 RA (redundant)

Thiazolidinediones (TZDs) ; • Pioglitazone (15–45 mg); • Rosiglitazone (4–8 mg) Peroxisome proliferator-activated receptor-gamma (PPAR- γ \gamma γ ) agonist; enhances insulin sensitivity in skeletal muscle, liver, and adipose. High ; (0.8–1.5%) • Weight gain (fluid retention + adipogenesis); • Reduces non-fatal MI/stroke (pioglitazone - PROactive / IRIS); • Resolves MASH/NASH • Fluid retention, peripheral edema, CHF exacerbation ; • Increased bone resorption → \rightarrow → distal extremity fractures in women; • Bladder cancer risk (pioglitazone long-term caution); • Macular edema • Black Box: NYHA Class III or IV Heart Failure (Absolute Contraindication) ; • Active bladder cancer / unexplained macroscopic hematuria; • Active hepatic disease (ALT >2.5x ULN)

Sulfonylureas (2nd Gen) ; • Glipizide (5–20 mg); • Glimepiride (1–8 mg); • Glyburide (1.25–20 mg) Closes ATP-sensitive potassium ( K ATP K_{\text{ATP}} K ATP ​ ) channels in β \beta β -cell membranes → \rightarrow → calcium influx → \rightarrow → glucose-independent insulin secretion. High ; (1.0–1.5%) • Weight gain (1–3 kg); • Neutral cardiorenal effect; • High rate of secondary failure ( β \beta β -cell burnout) • High Risk of Hypoglycemia (especially prolonged in renal impairment); • Weight gain; • Sulfa cross-reactivity (theoretical); • Blunting of ischemic myocardial preconditioning • Glyburide is Contraindicated in older adults (Beers Criteria) and CKD due to active metabolites with prolonged half-life.; • Glipizide is the preferred sulfonylurea in CKD (inactivated by liver)

Important

Board Exam Pharmacology Traps:

GLP-1 RA + DPP-4i Co-prescription: Never prescribe a DPP-4 inhibitor (e.g., sitagliptin) concurrently with a GLP-1 receptor agonist (e.g., semaglutide). They share overlapping incretin pathways; clinical trials demonstrate no additive HbA1c reduction while multiplying adverse effect liability.

Euglycemic DKA (euDKA) with SGLT2i: SGLT2 inhibitors can induce severe ketoacidosis with normal or minimally elevated blood glucose levels (often <200 mg/dL). SGLT2i must be discontinued at least 3 to 4 days prior to any major elective surgery or extreme endurance athletics, and ketone testing (blood β \beta β -hydroxybutyrate) must be executed if patients present with nausea, malaise, or dyspnea regardless of fingerstick glucose levels.

Linagliptin Advantage: Linagliptin (Tradjenta) is the only DPP-4 inhibitor eliminated primarily via the enterohepatic biliary system, requiring zero dose adjustment across all stages of renal impairment.

5. Insulin Therapy: Initiation, Titration Algorithms & Physiological Phenomena +---------------------------------------------------------------------------------------------------+

  • | BASAL-BOLUS INSULIN INITIATION & TITRATION PROTOCOL |
  • | |
  • | [STEP 1: INITIATE BASAL INSULIN] |
  • | - Agents: Glargine (Lantus/Toujeo), Detemir (Levemir), Degludec (Tresiba), or NPH |
  • | - Starting Dose: 10 units daily OR 0.1 - 0.2 units/kg/day administered at bedtime or morning |
  • | | |
  • | v |
  • | [STEP 2: TITRATE BASAL TO FASTING TARGET (80 - 130 mg/dL)] |
  • | - "Treat-to-Target": Increase dose by 2 units every 3 days until fasting glucose in target range|
  • | - If fasting hypoglycemia (<70 mg/dL): Immediately reduce basal dose by 10 - 20% (or 2-4 units)|
  • | - "Overbasalization Alert": If Basal dose > 0.5 units/kg/day without achieving HbA1c control, |
  • | STOP escalating basal and initiate prandial (bolus) coverage! |
  • | | |
  • | v |
  • | [STEP 3: ADD PRANDIAL (MEALTIME / BOLUS) INSULIN] |
  • | - Agents: Rapid-acting analogs (Lispro/Humalog, Aspart/Novolog, Glulisine/Apidra) or Regular |
  • | - Starting Dose: 4 units OR 10% of basal dose administered immediately (0-15 min) before meal |
  • | - Progression: Start with largest meal of the day ("Basal-Plus"); advance to "Basal-Bolus" |
  • | (prandial before each of 3 meals) if HbA1c remains above target. |
  • +---------------------------------------------------------------------------------------------------+
  • Dawn Phenomenon vs. Somogyi Effect: Diagnostic Differentiation

When a diabetic patient presents with unexplained, persistent early morning fasting hyperglycemia (7:00 AM blood glucose 200–260 mg/dL), the AGPCNP must differentiate between two distinct physiological phenomena by ordering a 3:00 AM capillary blood glucose check : +---------------------------------------------------------------------------------------------------+

  • | DAWN PHENOMENON VS. SOMOGYI EFFECT DIFFERENTIATION |
  • | |
  • | [MORNING FASTING HYPERGLYCEMIA (e.g., 220 mg/dL)] |
  • | | |
  • | v |
  • | [CHECK 3:00 AM BLOOD GLUCOSE] |
  • | | |
  • | +----------------------+----------------------+ |
  • | | | |
  • | v v |
  • | [3:00 AM HYPERGLYCEMIC] [3:00 AM HYPOGLYCEMIC] |
  • | (e.g., 140 - 180 mg/dL) (e.g., 40 - 60 mg/dL) |
  • | | | |
  • | v v |
  • | = DAWN PHENOMENON = SOMOGYI EFFECT |
  • | - Pathophysiology: Physiological surge of - Pathophysiology: Rebound hyperglycemia driven |
  • | nocturnal Growth Hormone, Cortisol, and by counter-regulatory hormones (epinephrine, |
  • | Glucagon stimulating hepatic gluconeogenesis. glucagon, cortisol) following nocturnal low. |
  • | - Clinical Action: INCREASE bedtime basal - Clinical Action: DECREASE bedtime basal |
  • | insulin dose OR shift NPH to bedtime. insulin dose OR give bedtime protein snack. |
  • +---------------------------------------------------------------------------------------------------+

6. Microvascular Complications: Surveillance & Evidence-Based Management +---------------------------------------------------------------------------------------------------+

  • | MICROVASCULAR COMPLICATION SURVEILLANCE TIMELINE |
  • | |
  • | COMPLICATION SCREENING MODALITY FREQUENCY DIAGNOSTIC THRESHOLD |
  • | --------------------------------------------------------------------------------------------- |
  • | Nephropathy (DKD) Spot Urine Albumin/Creatinine Annual UACR >= 30 mg/g |
  • | Ratio (UACR) + Serum eGFR (At diagnosis) eGFR < 60 mL/min |
  • | Retinopathy Dilated Eye Exam by Annual Microaneurysms, cotton |
  • | Optometrist / Ophthalmologist (At diagnosis) wool spots, neovasc. |
  • | Peripheral 10g Semmes-Weinstein Mono- Annual Loss of protective |
  • | Neuropathy (DSPN) filament + 128Hz Tuning Fork (At diagnosis) sensation (>=2 sites) |
  • | Autonomic Orthostatic vitals, Resting HR, Annual Orthostatic drop, resting|
  • | Neuropathy GI / GU / erectile review (At diagnosis) tachycardia (>100 bpm) |
  • | Comprehensive Visual inspection, pulses, Annual Ulcers, calluses, loss |
  • | Foot Examination monofilament, pedal deformity (Every visit*) of sensation, ABI <0.90 |
  • | |
  • | *Visual foot inspection should be conducted at every routine diabetes clinical encounter. |
  • +---------------------------------------------------------------------------------------------------+
  • A. Diabetic Kidney Disease (DKD)

Diagnostic Staging via Albuminuria:

Normal: UACR < 30 mg/g \text{UACR} < 30\text{ mg/g} UACR < 30 mg/g .

Microalbuminuria (Moderately Increased): UACR 30 – 299 mg/g \text{UACR } 30\text{--}299\text{ mg/g} UACR 30 – 299 mg/g .

Macroalbuminuria (Severely Increased / Overt Nephropathy): UACR ≥ 300 mg/g \text{UACR } \ge 300\text{ mg/g} UACR ≥ 300 mg/g .

Mandatory Diagnostic Protocol: Two of three spot UACR specimens collected within a 3- to 6-month period must be elevated to confirm DKD (due to transient spikes from exercise, infection, fever, or severe hypertension).

Four Pillars of DKD Pharmacotherapy:

ACE Inhibitor or ARB: Titrated to maximum tolerated dose if UACR ≥ 30 mg/g \ge 30\text{ mg/g} ≥ 30 mg/g . (Do NOT combine ACEi + ARB).

SGLT2 Inhibitor (Empagliflozin, Dapagliflozin, Canagliflozin): Initiate in all patients with eGFR 20 – 60 mL/min \text{eGFR } 20\text{--}60\text{ mL/min} eGFR 20 – 60 mL/min or UACR ≥ 30 mg/g \text{UACR } \ge 30\text{ mg/g} UACR ≥ 30 mg/g to retard GFR decline and ESRD progression.

Non-Steroidal Mineralocorticoid Receptor Antagonist (Finerenone / Kerendia): Indicated for persistent albuminuria ( UACR ≥ 30 mg/g \text{UACR } \ge 30\text{ mg/g} UACR ≥ 30 mg/g ) on maximally tolerated ACEi/ARB and SGLT2i with eGFR ≥ 25 mL/min \text{eGFR } \ge 25\text{ mL/min} eGFR ≥ 25 mL/min and serum potassium ≤ 5.0 mEq/L \le 5.0\text{ mEq/L} ≤ 5.0 mEq/L (FIDELIO-DKD / FIGARO-DKD trials).

Strict Blood Pressure & Glycemic Control: BP target < 130 / 80 mmHg <130/80\text{ mmHg} < 130/80 mmHg ; HbA1c individualized (~7.0%).

B. Diabetic Retinopathy

Epidemiology & Screening: Diabetic retinopathy is the leading cause of blindness in working-age adults. In T2DM, screen with a comprehensive dilated eye exam at the time of diagnosis and annually thereafter. (If exams are normal and glycemia is well-controlled, screening may occur every 2 years).

Stages:

Non-Proliferative Diabetic Retinopathy (NPDR): Microaneurysms, dot-and-blot hemorrhages, hard lipid exudates, macular edema (primary cause of visual loss), and cotton wool spots (nerve fiber layer micro-infarctions).

Proliferative Diabetic Retinopathy (PDR): Characterized by pathological neovascularization (fragile new blood vessels stimulated by VEGF ischemia) extending into the vitreous, vitreous hemorrhage, preretinal hemorrhage, and tractional retinal detachment.

Therapy: Intravitreal anti-VEGF agents (aflibercept, ranibizumab, bevacizumab), panretinal laser photocoagulation (PRP), and vitrectomy.

C. Diabetic Peripheral Neuropathy (Distal Symmetric Polyneuropathy - DSPN)

Clinical Presentation: Classic "stocking-glove" distribution beginning in the distal toes and ascending bilaterally. Positive symptoms (burning, stabbing dysesthesias, hyperalgesia, allodynia) and negative symptoms (numbness, loss of proprioception, sensory ataxia).

Physical Examination: Annual evaluation using the 10g Semmes-Weinstein Monofilament across plantar surfaces (loss of sensation at ≥ 2 \ge 2 ≥ 2 sites indicates loss of protective sensation and high ulceration risk), combined with testing of vibration perception using a 128-Hz tuning fork , pinprick sensation, and Achilles deep tendon reflexes (early loss of ankle jerks).

Pharmacological Pain Management (FDA-Approved):

Duloxetine (Cymbalta): 60 mg daily (SNRI; also manages comorbid depressive symptoms; avoid in severe hepatic/renal impairment).

Pregabalin (Lyrica): 150–300 mg/day divided BID/TID ( α 2 - δ \alpha_2\text{-}\delta α 2 ​ - δ calcium channel ligand; dose-dependent sedation, peripheral edema, renally cleared).

Gabapentin (Neurontin): 300–1,800 mg/day divided TID (off-label first-line; sedation, dizziness).

Capsaicin 8% Topical Patch or Pregabalin/Duloxetine combinations for refractory pain. (Note: Opioids and tramadol should be strictly avoided due to addiction liability and lack of long-term efficacy).

D. Diabetic Autonomic Neuropathy (DAN)

Cardiovascular Autonomic Neuropathy (CAN): Resting tachycardia ( > 100 bpm >100\text{ bpm} > 100 bpm ), fixed heart rate unvarying with deep respiration, orthostatic hypotension (drop in SBP ≥ 20 mmHg \text{SBP} \ge 20\text{ mmHg} SBP ≥ 20 mmHg or DBP ≥ 10 mmHg \text{DBP} \ge 10\text{ mmHg} DBP ≥ 10 mmHg on standing), painless ("silent") myocardial infarction.

Diabetic Gastroparesis: Delayed gastric emptying in the absence of mechanical obstruction. Symptoms: early satiety, postprandial fullness, severe nausea, intractable vomiting of undigested food, erratic glycemic control with frequent unexplained postprandial hypoglycemia. Diagnosis: Gastric Emptying Scintigraphy using a radiolabeled solid meal (retention > 10 % >10\% > 10% at 4 hours is diagnostic). Treatment: small frequent low-fat/low-fiber meals, optimization of blood glucose, oral Metoclopramide (Reglan - limit to < 12 weeks <12\text{ weeks} < 12 weeks due to black box warning for tardive dyskinesia), oral Erythromycin (motilin receptor agonist for acute flares), and antiemetics.

Genitourinary Autonomic Neuropathy: Diabetic cystopathy (atonic bladder, sensory loss of bladder fullness, overflow urinary incontinence, high post-void residuals predisposing to recurrent UTIs), erectile dysfunction (PDE-5 inhibitors: sildenafil, tadalafil), retrograde ejaculation.

7. Hyperglycemic Crises: DKA vs. Hyperosmolar Hyperglycemic State (HHS) +---------------------------------------------------------------------------------------------------+

  • | ACUTE HYPERGLYCEMIC CRISIS DECISION MATRIX |
  • | |
  • | DIAGNOSTIC FEATURE DIABETIC KETOACIDOSIS (DKA) HYPEROSMOLAR HYPERGLYCEMIC |
  • | STATE (HHS) |
  • | --------------------------------------------------------------------------------------------- |
  • | Typical Patient Population Type 1 DM (can occur in T2DM) Type 2 DM (Frail / Elderly) |
  • | Speed of Clinical Onset Rapid (< 24 hours) Insidious (Days to Weeks) |
  • | Plasma Glucose Level >= 200 or known diabetes >= 600 mg/dL (frequently >1000)|
  • | Arterial / Venous pH < 7.30 (Severe < 7.00) > 7.30 |
  • | Serum Bicarbonate (HCO3-) < 18 mEq/L (Severe < 10 mEq/L) > 18 mEq/L |
  • | Urine / Serum Ketones Strongly Positive (3+) Negative or Trace |
  • | Serum Beta-hydroxybutyrate Markedly Elevated (>3.0 mmol/L) Normal or Mildly Elevated |
  • | Effective Serum Osmolality Variable (< 320 mOsm/kg) > 320 mOsm/kg |
  • | Serum Anion Gap Elevated (> 12 mEq/L) Normal or Mildly Elevated |
  • | Mental Status Alteration Alert to Stuporous Profound Stupor / Coma |
  • | Mortality Rate 1 - 3% 10 - 20% |
  • +---------------------------------------------------------------------------------------------------+

Critical Management Algorithms for Acute Hyperglycemic Emergencies:

Fluid Resuscitation: Isotonic 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl or a balanced crystalloid at 500 – 1 , 000 mL/hr 500\text{--}1,000\text{ mL/hr} 500 – 1 , 000 mL/hr for the first 2–4 hours (smaller 250 mL boluses in older adults, heart failure, or dialysis). When serum sodium is corrected ( [ Na + ] + 0.016 × [ Glucose − 100 ] [\text{Na}^+] + 0.016 \times [\text{Glucose} - 100] [ Na + ] + 0.016 × [ Glucose − 100 ] ), switch to 0.45 % NaCl 0.45\%\text{ NaCl} 0.45% NaCl if corrected sodium is normal or elevated.

Potassium Repletion (The Absolute Rule): Check serum potassium before administering insulin. Under the 2024 adult consensus, if serum K + < 3.5 mEq/L \mathbf{K^+ < 3.5\text{ mEq/L}} K + < 3.5 mEq/L , HOLD INSULIN and administer IV potassium chloride (about 10 mEq/hr 10\text{ mEq/hr} 10 mEq/hr ) until K + > 3.5 mEq/L K^+ > 3.5\text{ mEq/L} K + > 3.5 mEq/L to prevent fatal arrhythmias from insulin-induced intracellular potassium shifting. If K + K^+ K + is 3.5–5.0 mEq/L, give potassium with IV fluids and start insulin. If K + > 5.0 mEq/L K^+ > 5.0\text{ mEq/L} K + > 5.0 mEq/L , start insulin without potassium, recheck K + K^+ K + 2 hours after insulin starts and then every 4 hours, and add potassium once it falls below 5.0.

Insulin Administration: IV Regular insulin continuous infusion ( 0.1 units/kg/hr 0.1\text{ units/kg/hr} 0.1 units/kg/hr or 0.14 units/kg/hr 0.14\text{ units/kg/hr} 0.14 units/kg/hr without bolus). When blood glucose falls below 250 mg/dL in DKA (or reaches 300 mg/dL in HHS), add 5-10% dextrose to IV fluids and reduce insulin to about 0.05 units/kg/hr, continuing until ketoacidosis resolves. DKA is resolved when plasma ketone (β-hydroxybutyrate) is <0.6 mmol/L and venous pH is ≥7.3 or bicarbonate is ≥18 mEq/L (ideally glucose <200 mg/dL); the anion gap and urine ketones are not used as resolution criteria.

8. Board-Yield Summary & Clinical Pearls +---------------------------------------------------------------------------------------------------+

  • | ANCC AGPCNP CLINICAL EXAM PEARLS |
  • | |
  • | - Cardiorenal Protection is Independent of Baseline HbA1c: In patients with established ASCVD, |
  • | Heart Failure (HFrEF/HFpEF), or CKD (UACR >=30 or eGFR 20-60), ALWAYS add an SGLT2i or GLP-1 RA|
  • | with demonstrated outcome trials (EMPA-REG, DAPA-HF, CREDENCE, LEADER) regardless of A1c. |
  • | |
  • | - SGLT2i Renal Threshold: SGLT2 inhibitors lose their glycemic/glucose-lowering efficacy when |
  • | eGFR <45 mL/min, BUT retain robust nephroprotective and cardiovascular failure benefits down |
  • | to eGFR 20 mL/min. NEVER discontinue an SGLT2i simply because eGFR dropped to 30 mL/min! |
  • | |
  • | - Metformin eGFR Cutoffs: eGFR >=45 (Full dose, 2000 mg/day); eGFR 30-44 (Max dose 1000 mg/day;|
  • | do not initiate new therapy); eGFR <30 (Absolute Contraindication; discontinue immediately). |
  • | |
  • | - Incretin Rules: NEVER combine GLP-1 RA + DPP-4i (no additive glycemic benefit; redundant). |
  • | Linagliptin is the ONLY DPP-4i that requires NO renal dose reduction. |
  • | |
  • | - 3:00 AM Blood Glucose Rule: 3:00 AM High = Dawn Phenomenon (Increase bedtime basal insulin); |
  • | 3:00 AM Low = Somogyi Effect (Decrease bedtime basal insulin or give bedtime snack). |
  • +---------------------------------------------------------------------------------------------------+